| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827907 | European Urology Focus | 2017 | 9 Pages |
Abstract
Matched patient-derived clear cell renal cell carcinoma xenografts and cell lines from responsive and refractory patients treated with sunitinib were established and evaluated for pharmacologic response to anti-vascular endothelial growth factor treatment. Both models accurately reflected the genetic characteristics of original tumors, but only xenografts recapitulated drug responses observed in patients. These models could serve as a powerful platform for precision medicine.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Yiyu Dong, Brandon J. Manley, Maria F. Becerra, Almedina Redzematovic, Jozefina Casuscelli, Daniel M. Tennenbaum, Ed Reznik, Song Han, Nicole Benfante, Ying-Bei Chen, Maria E. Arcila, Omer Aras, Martin H. Voss, Darren R. Feldman, Robert J. Motzer,